Skip to main
  1. Stocks
  2. Anteris Technologies Global Corp
  3. Forecast
AVR

AVR Stock Forecast & Price Target

AVR Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 67%
Hold 33%
Sell 0%
Strong Sell 0%

Bulls say

Anteris Technologies Glb is viewed positively because DurAVR’s single-piece, biomimetic design is positioned as a structural leap over existing TAVR valves, with physician-led feedback, head-to-head PARADIGM testing, and early hemodynamic data suggesting native-valve-like flow and lower gradients than competitors. The company also has unusually strong clinical and strategic validation, including 130+ EFS/EMBARK patients, ~200 patients treated to date, a 55,000+ patient history behind ADAPT tissue, and Medtronic’s $90M investment, all of which support the view that the platform is being de-risked while demand remains high. Financially, it ended 2Q26 with $260.9M in cash, R&D rose 34% Q/Q to $23.4M as manufacturing and trial infrastructure scaled, and full French clearance expands PARADIGM into one of Europe’s largest TAVR markets, reinforcing runway and growth optionality.

Bears say

Anteris Technologies Glb is facing a highly uncertain fundamental backdrop because its valuation depends heavily on PARADIGM trial outcomes and eventual FDA commercial approval, both of which could disappoint relative to management and analyst expectations or take longer than the company can comfortably fund. The company has already incurred significant operating losses and negative cash flow to support development, raising the risk that expenses continue to outpace resources and push it toward inoperability if capital needs increase. In addition, DurAVR still lacks a proven marketing or sales strategy, which could slow adoption by the medical community and leave the business without a clear path to meaningful commercialization.

AVR has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 67% recommend Buy, 33% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Anteris Technologies Global Corp and is not a guaranteed prediction by Public.com or investment advice.

AVR Analyst Forecast & Price Prediction

Get the latest AVR stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AVR

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Anteris Technologies Global Corp (AVR) Forecast

Analysts have given AVR a Buy based on their latest research and market trends.

According to 3 analysts, AVR has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Anteris Technologies Global Corp (AVR)


AVR Analyst Forecast & Price Prediction

Get the latest AVR stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in AVR

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover AVR stock data and trends